Search results

Selecting the most appropriate healthcare waste treatment technology (HCWTT) is an uncertain and complex decision-making problem because there exist more than one alternative and many conflicting qualitative and quantitative criteria. However, the use of fuzzy and comparative values, instead of specific crisp values, provides more accurate results, so that the alternatives may be evaluated in accordance with hesitant human nature. The purpose of this paper is to select the best HCWTT using a hesitant fuzzy linguistic term set (HFLTS).

Five main criteria were identified for HCWTT selection, such as economic, social, environmental, technical and ergonomic criteria. In total, 19 sub-criteria were examined, and the hierarchy of the criteria was formed. The criteria weights were determined using the multi-criteria hesitant fuzzy linguistic term set (MC-HFLTS). The selection processes of incineration (A₁), steam sterilization (A₂), microwave (A₃) and landfill (A₄) alternatives were carried out using the multi-attributive ideal-real comparative analysis (MAIRCA) and multi-attributive border approximation area comparison (MABAC) methods. In the comparative analyses, Vise Kriterijumska Optimizacija I Kompromisno Resenje (VIKOR) and technique for order preference by similarity to an ideal solution (TOPSIS) methods were used.

The comparison of the results of the MABAC and MAIRCA methods with the results of VIKOR and TOPSIS methods indicated that A₂ (steam sterilization) alternative was the best one and produced the same ranking of the technology alternatives (A₂ > A₃ > A₁ > A₄). As a result, the study concluded that these methods can be successfully used for HCWTT selection problems.

To the best of the authors’ knowledge, MC-HFLTS has not been used to select HCWTT in the existing literature. For the first time, MC-HFLTS&MAIRCA and MC-HFLTS&MABAC approaches were used in order to choose the best treatment method for healthcare waste under the effect of multiple conflicting hierarchical criteria. It has been provided that MABAC and MAIRCA select alternative choices by taking into consideration the hierarchical criteria. Unlike other studies, this study also considered ergonomic criteria that are important for people working during the process of using the treatment technology.

Wellness tourism is complex due to the varied expectations and perceptions of tourists. This study attempts to explore components that shape tourist expectations of health treatments and tourist attractions, which have not been deeply explored in the extant literature.

A scoping review of the literature published between 2000 and 2021 was conducted to reach the conclusions of this study. Out of 303 literature sources, a total of 105 literature sources were retained for the final analysis.

Findings show that tourists expect a mix of health treatments, such as conventional medical treatments and alternative health treatments and tourist attractions, as part of wellness tourism to improve their health and well-being (HWB). A favorable trade-off between tourist expectations and their perception of wellness tourism impacts tourist HWB and behavioral intention.

The proposed wellness tourism conceptual model and wellness tourism matrix may help wellness tourism service providers to understand tourist expectations for health treatments and tourist attractions in a recent context. Wellness tourism service providers may follow the guidelines outlined in this study to offer health treatments and tourist attractions according to tourist expectations, which may result in the favorable behavioral intentions of wellness tourists.

This study unravels the previously under-explored role of conventional medical treatments, which arguably fall under the category of allopathic medical treatment, in wellness tourism. Destination marketing organizations may focus on the wellness philosophies of health treatments and tourist attractions to meet the growing expectations of wellness tourists for HWB, as outlined in the literature review. This study provides insights into the different components of contemporary wellness tourism those impact wellness tourists' cognitive responses, HWB and behavioral intention.

The purpose of this paper is to describe an application of Multi-Criteria Decision Making (MCDM) technique for the selection of waste treatment and disposal technology for municipal solid waste (MSW).

The proposed approach is based on the integration of Delphi and Analytic Hierarchy Process (AHP) techniques. A model has been proposed to evaluate the best treatment and disposal technology. Expert opinions have been incorporated in the selection of criteria. AHP has been used to determine the weights of criteria, followed by ranking of the available technologies.

Delphi method was used to derive appropriate evaluation criteria to assess the potential alternative technologies. A set of identified holistic criteria was used, representing the environmental, social, and economic aspects, as compared to the sub-criteria concept generally found in existing literature. Quantitative weightings from the AHP model were calculated to identify the priorities of alternatives. The study provides a simple framework for technology selection as compared to the complex models present in the literature, reducing the uncertainty, cost and time consumed in the decision-making process.

The model identifies the optimal technologies for the handling, treatment and disposal of MSW in a better economic and more environmentally sustainable way. The study provides a simple framework for selection as compared to the complex models present in the literature, reducing the uncertainty, cost and time taken by the decision-making process.

The paper highlights a new insight into MCDM techniques to select an optimum treatment and disposal technology suitable for MSW management in India. The study identifies a minimal relevant set of evaluation criteria, and appropriate technologies for the handling, treatment, and disposal of MSW in a more economic and environmentally sustainable way.

Negotiators with a BATNA (best alternative to the negotiated agreement) obtain higher individual outcomes and a larger percentage of the dyadic outcomes than individuals without a BATNA. This study examined if three mechanisms related to a BATNA, an alternative, a specific goal, and self‐efficacy, independently or in combination, influence outcomes. Six of the eight combinations resulted in higher individual outcomes. An alternative coupled with a goal or self‐efficacy resulted in a higher percent of dyadic outcomes and higher impasse rates.

Although the intention of the International Accounting Standards Board (IASB) is not to permit choices in the accounting treatment of similar transactions and events, International Financial Reporting Standards (IFRSs) still contain various choices of accounting treatment. Different accounting alternatives for similar transactions limit the comparability of financial information. Certain accounting policies result in differences in recognition, measurement and disclosures. This article identifies 16 such accounting policy choices and presents the descriptive empirical results on which accounting policies were in fact chosen by a sample of 157 South African listed companies, in cases where IFRSs allow a choice between alternative accounting policies. Disclosure of accounting policies is necessary for the users of financial statements to enable them to compare the financial statements of various entities in making economic decisions. The research also found a lack of disclosures relating to chosen accounting policies in limited cases.

The purpose of this study is to explore the determinants of consumer's propensity to choose non‐conventional treatment protocols using control theory as the theoretical framework.

Data were collected from a consumer panel using a self‐administered questionnaire. The sample consisted of 350 US‐based “Baby Boomer” consumers.

The results of this study indicate that consumers' health locus of control self‐efficacy, and neuroticism impact their propensity to use non‐conventional treatments. Contrary to previous studies, consumers' health value was not a significant moderator except in the case of internal health locus of control.

The findings of this study provide guidance to public policy makers, health care providers, and managers of the conventional and non‐conventional pharmaceutical industries. Specially, the results reify the importance of the collaborative efforts of public policy makers and health care practitioners alike to proactively inform consumers of the issues underlying unsupervised use of non‐conventional medications. The results suggest greater governance is needed to control the marketing of non‐conventional medications. Overall, this research provides prescriptive guidance for marketers of both non‐conventional and conventional treatments, suggesting how better promotional and integrated communications may effectively serve their target markets.

The paper examines an unexplored yet rapidly growing consumption behavior in the USA: the unprecedented use of non‐conventional treatments. Evaluation of this consumer trend has largely focused on demographic factors relative to adopters (and non‐adopters). Control theory affords a conceptual foundation for exploring individual‐level factors that have been overlooked in previous empirical studies.

Purpose – Objective measures of a new treatment's expected ability to improve patients’ health are presumed to be significant factors influencing physicians’ treatment decisions. Physicians’ behavior may also be influenced by their patients’ disease severity and insurance reimbursement policies, firm promotional activities and public media reports. This chapter examines how objective evidence of the incremental effectiveness of novel drugs to treat cancer (“chemotherapies”) impacts the rate at which physicians’ adopt these treatments into practice, holding constant other factors.

Design/methodology – The novelty of the analysis resides in the dataset and estimation strategy employed. Data is derived from a United States population-based chemotherapy order entry system, IntrinsiQ Intellidose. Quality/price endogeneity is overcome by employing sample selection methods and an estimation strategy that exploits quality variation at the molecule-indication level. Pooled diffusion rates across molecule-indication pairs are estimated using nonparametric hazard models.

Findings – Results suggest incremental effectiveness is negatively and nonsignificantly associated with the diffusion of new chemotherapies; faster rates of diffusion are positively and significantly related to low five-year survival probabilities and measures of perceived clinical significance. Results are robust to numerous specification checks, including a measure of alternative therapeutic availability. We discuss the magnitude and potential direction of bias introduced by several threats to internal validity. Evidence of incremental effectiveness does not appear to motivate the rate of specialty physician diffusion of new medical treatment; in all models high risk of disease mortality and perceptions of therapeutic quality are significant drivers of physician use of novel chemotherapies.

Value/originality – Understanding the rate of technological advance across different clinical settings, as well as the product-, provider-, and patient-level determinants of this rate, is an important subject for future research.

Assessing the capacity of individuals with learning disabilities to make decisions about treatment is problematic. This field has received little attention in the United Kingdom, the concept of capacity proving difficult to define. There are no commonly agreed standards, English law in this area is still developing and there are few guidelines to instruct health professionals. This paper reviews the diagnostic, outcome and functional approaches to examining the issue of capacity and outlines a number of tests that have been developed for use in the clinical setting, though not adapted for use with people with a learning disability. Issues to be addressed in the adaptation of tests are explored and areas for practitioners to consider are discussed.

The purpose of this paper is to analyse the accounts of Swedish cardiologists concerning patient involvement in consultations for atrial fibrillation (AF). The questions were: how cardiologists handle and provide scope for patient involvement in medical consultations regarding AF treatment and how cardiologists describe their familiarity with shared decision-making.

A descriptive study was designed. Ten interviews with cardiologists at four Swedish hospitals were held, and a qualitative content analysis was performed on the collected data.

The analysis shows cardiologists’ accounts of persuasive practice, protective practice, professional role and medical craftsmanship when it comes to patient involvement and shared decision-making. The term “shared decision-making” implies a concept of not only making one decision but also ensuring that it is finalised with a satisfactory agreement between both parties involved, the patient as well as the cardiologist. In order for the idea of patient involvement to be fulfilled, the two parties involved must have equal power, which can never actually be guaranteed.

Methodologically, this paper reflects the special contribution that can be made by the research design of descriptive qualitative content analysis (Krippendorff, 2004) to reveal and understand cardiologists’ perspectives on patient involvement and participation in medical consultation and shared decision-making. The utility of this kind of analysis is to find what cardiologists said and how they arrived at their understanding about patient involvement. Accordingly, there is no quantification in this type of research.

Cardiologists should prioritise patient involvement and participation in decision-making regarding AF treatment decisions in consultations when trying to meet the request of patient involvement.

Theoretically, the authors have learned that the patient involvement and shared decision-making requires the ability to see patients as active participants in the medical consultation process.

The purpose of this paper is to give an overview of the scientific evidence for reduced drinking in alcohol use disorders. While the aim of alcohol use disorders (AUD) treatment usually focuses on abstinence, only a minority of individuals with AUD enter treatment. Lack of alternative treatment goals, including reduced drinking instead of abstinence, have been identified as a potential barrier for treatment entry. Epidemiological and treatment outcome studies reveal that a large proportion of individuals with AUD are able to substantially reduce their alcohol intake for a prolonged duration of time.

A narrative review of the literature on prevalence rates and health effects as well as evidence-based approaches fostering reduced drinking in individuals with AUD is presented.

Reduced drinking is associated with improvements in both morbidity and mortality. Research has identified evidence-based psychosocial and pharmacological treatment approaches; however, implementation is still scarce.

Target groups for interventions fostering drinking reduction instead of abstinence are defined and desiderata for further research are outlined.